Caelyx

DRUG6 trials

Sponsors

North Eastern German Society of Gynaecological Oncology, Universitaire Ziekenhuizen KU Leuven, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Ludwig Institute for Cancer Research, Xian-Janssen Pharmaceutical Ltd.

Conditions

Advanced Solid TumorsBreast CancerElderlyEpithelial Ovarian CancerLymphomasOvarian CancerOvarian NeoplasmsSolid Tumors

Phase 1

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

WithdrawnNCT01490047

Ludwig Institute for Cancer ResearchLymphomas, Solid Tumors

Start: 2013-01-31Updated: 2015-06-16

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

TerminatedNCT03387917

Swiss Cancer InstituteAdvanced Solid Tumors

Start: 2018-11-12End: 2023-12-22Updated: 2024-12-02

Phase 2

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

CompletedNCT00170573

North Eastern German Society of Gynaecological OncologyOvarian Cancer

Start: 2001-09-30End: 2010-08-31Updated: 2024-12-16

Caelyx Adjuvant in Elderly Breast Cancer

CompletedNCT00284336

Universitaire Ziekenhuizen KU LeuvenBreast Cancer, Elderly

Start: 2006-01-31End: 2007-04-30Target: 16Updated: 2014-12-09

Phase 3

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

TerminatedNCT00653952

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Ovarian Neoplasms

Start: 1997-05-31End: 2000-04-30Updated: 2010-04-27

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

TerminatedNCT01840943

Xian-Janssen Pharmaceutical Ltd.Epithelial Ovarian Cancer

Start: 2013-06-30End: 2014-08-31Updated: 2015-12-23

Related Papers

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

2025-11-18

Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

Cancer Chemotherapy and Pharmacology2024-06-157 citations

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).

2024-02-0210 citations

TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).

Journal of Clinical Oncology2022-06-011 citations